Citadel Advisors’s Turnstone Biologics TSBX Stock Holding History

Citadel Advisors’s Portfolio TSBX Stock Details TSBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-208,887	Closed	-$75K	–	14141
2025 Q2	$75K	Buy	+208,887	New	+$73.2K	﹤0.01%	11538
2025 Q1	–	Sell	-689,213	Closed	-$342K	–	15587
2024 Q4	$342K	Hold	689,213	–	–	﹤0.01%	9383
2024 Q3	$384K	Buy	689,213 +4,580	+0.7%	+$7.03K	﹤0.01%	8807
2024 Q2	$1.79M	Sell	684,633 -204	-0%	-$583	﹤0.01%	5525
2024 Q1	$1.79M	Sell	684,837 -3,631	-0.5%	-$10.4K	﹤0.01%	5735
2023 Q4	$1.72M	Buy	688,468 +1,016	+0.1%	+$2.65K	﹤0.01%	5631
2023 Q3	$2.66M	Buy	+687,452	New	+$6.13M	﹤0.01%	4714

Citadel Advisors's TSBX Position: Q3 2025 in Review

Citadel Advisors sold out of Turnstone Biologics (TSBX) in Q3 2025, closing a stake of 208,887 shares — an estimated $75K sold.

Citadel Advisors first reported a position in TSBX in Q3 2023 and held it in 7 quarters. The position peaked at $2.66M in Q3 2023. 1 fund tracked by Wall St. Rank holds TSBX as of Q3 2025.

Citadel Advisors reported no remaining Turnstone Biologics position as of Q3 2025 after selling out during the quarter.
Citadel Advisors sold 208,887 Turnstone Biologics shares in Q3 2025, an estimated $75K.
Citadel Advisors first reported a position in Turnstone Biologics in Q3 2023 and held it in 7 quarters.
Citadel Advisors's Turnstone Biologics position peaked at $2.66M in Q3 2023.
1 fund tracked by Wall St. Rank held Turnstone Biologics as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.